We are live on ! Find out more
CTA

Carillon Tower Advisers Portfolio holdings

AUM $16.4B
1-Year Est. Return 64.75%
This Fund
S&P 500
This Quarter Est. Return
+4.55%
1 Year Est. Return
+64.75%
3 Year Est. Return
+147.06%
5 Year Est. Return
10 Year Est. Return
AUM
$12.9B
AUM Growth
+$12.9B
Cap. Flow
+$2.44B
Cap. Flow %
18.95%
Top 10 Hldgs %
13.49%
Holding
489
New
192
Increased
92
Reduced
78
Closed
35

Top Sells

Rank Stock Value
1
HQY icon
HealthEquity
HQY
+$34.8M
2
RCL icon
Royal Caribbean
RCL
+$33.2M
3
OMCL icon
Omnicell
OMCL
+$29.2M
4
TYL icon
Tyler Technologies
TYL
+$29.1M
5
CGNX icon
Cognex
CGNX
+$28.3M

Sector Composition

Rank Sector Weight
1 Healthcare 18.54%
2 Technology 17.46%
3 Industrials 16.92%
4 Consumer Discretionary 15.93%
5 Financials 10.9%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
INFN
151
DELISTED
Infinera Corporation Common Stock
INFN
$29.5M 0.23%
2,768,997
SNPS icon
152
Synopsys
SNPS
$71.6B
$29.4M 0.23%
364,550
+50,321
+16% +$4.42M
CHRW icon
153
C.H. Robinson
CHRW
$20.5B
$29.2M 0.23%
317,086
+31,047
+11% +$2.86M
MU icon
154
Micron Technology
MU
$835B
$29.1M 0.23%
582,157
-309,779
-35% -$14.8M
MXIM
155
DELISTED
Maxim Integrated Products
MXIM
$29.1M 0.23%
+506,381
New +$30M
MPC icon
156
Marathon Petroleum
MPC
$90.1B
$28.9M 0.22%
+394,700
New +$27.2M
AOS icon
157
A.O. Smith
AOS
$8.55B
$28.8M 0.22%
468,057
+56,700
+14% +$3.66M
MSCC
158
DELISTED
Microsemi Corp
MSCC
$28.8M 0.22%
445,981
AIMT
159
DELISTED
Aimmune Therapeutics
AIMT
$28.6M 0.22%
964,906
-590,828
-38% -$20.8M
CMA
160
DELISTED
Comerica
CMA
$28.6M 0.22%
+297,775
New +$28.4M
CCI icon
161
Crown Castle
CCI
$34.6B
$28.3M 0.22%
259,755
-171,996
-40% -$18.7M
PGNX
162
DELISTED
Progenics Pharmaceuticals Inc
PGNX
$28.1M 0.22%
3,948,024
+285,906
+8% +$1.9M
MSFT icon
163
Microsoft
MSFT
$2.9T
$27.8M 0.22%
313,619
-12,445
-4% -$1.14M
CWH icon
164
Camping World
CWH
$384M
$27.7M 0.22%
935,381
HUN icon
165
Huntsman Corp
HUN
$2.1B
$27.1M 0.21%
958,574
+164,054
+21% +$5.37M
KYNB
166
Kyntra Bio
KYNB
$27.4M
$27M 0.21%
24,039
FHN icon
167
First Horizon
FHN
$12.2B
$27M 0.21%
+1,433,725
New +$28.2M
VECO icon
168
Veeco
VECO
$2.62B
$26.6M 0.21%
1,632,083
EYE icon
169
National Vision
EYE
$1.76B
$26.5M 0.21%
835,811
+603,867
+260% +$22M
LEN icon
170
Lennar Class A
LEN
$20.4B
$26.4M 0.21%
479,496
-387,906
-45% -$23.4M
FOLD
171
DELISTED
Amicus Therapeutics
FOLD
$26.3M 0.2%
1,859,320
JPM icon
172
JPMorgan Chase
JPM
$916B
$26.2M 0.2%
242,597
-9,626
-4% -$1.09M
ZGNX
173
DELISTED
Zogenix, Inc.
ZGNX
$26.1M 0.2%
693,531
LUV icon
174
Southwest Airlines
LUV
$21.7B
$26M 0.2%
478,464
+60,640
+15% +$3.64M
AVXS
175
DELISTED
AveXis, Inc. Common Stock
AVXS
$25.8M 0.2%
217,163

Similar funds

Carillon Tower Advisers's Q1 2018 Portfolio in Review

As of Q1 2018, Carillon Tower Advisers held 489 positions worth $12.9B, up 136,756% from $9.4M the previous quarter. Its ten largest holdings account for 13% of the portfolio.

Carillon Tower Advisers deployed $2.44B of net new capital in Q1 2018, opening 192 new positions and adding to 92 existing holdings. Its largest new stake was Voya Financial: 871,250 shares worth $4.4M.

By sector, the portfolio is most concentrated in Healthcare at 19% of assets, down from 25% a quarter earlier, followed by Technology and Industrials.

On the sell side, the largest reduction was HealthEquity, an estimated $34.8M trimmed.

  • Carillon Tower Advisers's largest Q1 2018 buy was Voya Financial: 871,250 shares worth $4.4M.
  • Carillon Tower Advisers added most to DXC Technology in Q1 2018, an estimated $101M increase.
  • Carillon Tower Advisers's biggest Q1 2018 reduction was HealthEquity, cutting an estimated $34.8M.
  • Carillon Tower Advisers fully exited Prestige Consumer Healthcare in Q1 2018, selling an estimated $404K.
  • Carillon Tower Advisers's ten largest holdings make up 13% of its $12.9B portfolio in Q1 2018.
  • Carillon Tower Advisers opened 192 new positions and closed 35 in Q1 2018.
  • Carillon Tower Advisers's portfolio value rose 136,756% quarter-over-quarter to $12.9B.

Based on Carillon Tower Advisers's 13F filing for Q1 2018, filed 14 May 2018.